Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.63 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211762 | 0.83 | MAPT (0.47) | NPC1RAB9AKDM4EMAPTNPSR1 | |
| SCHEMBL5210861 | 0.83 | MAPT (0.50) | NPC1RAB9AKDM4EMAPTNPSR1 | |
| SCHEMBL5241709 | 0.82 | MAPT (0.44) | MCHR1CHRM1HTR2AAVPR1BNPC1 | |
| SCHEMBL5241697 | 0.82 | MAPT (0.44) | MCHR1CHRM1HTR2AAVPR1BKDM4E | |
| SCHEMBL5241704 | 0.82 | MAPT (0.44) | MCHR1CHRM1HTR2AAVPR1BKDM4E | |
| SCHEMBL5214683 | 0.82 | MEN1 (0.46) | KDM4EMAPTNPSR1MAPK1KMT2A | |
| SCHEMBL5208822 | 0.81 | MCHR1 (0.55) | MCHR1CHRM1HTR2ACACNA1GATM | |
| SCHEMBL5208465 | 0.80 | MAPT (0.49) | GAANPC1RAB9AKDM4EMAPT | |
| SCHEMBL5214838 | 0.80 | KDM4E (0.49) | NPC1RAB9AKDM4EMAPTNPSR1 | |
| SCHEMBL5213161 | 0.79 | MAPT (0.49) | NPC1RAB9AKDM4EMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | MCHR1 1777/4885CHRM1 1679/4885HTR2A 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.